Menu
No results found.
Weekly Share Price & Valuation Overview
TRAD CHI MED
China Traditional Chinese Medicine Holdings Co. Limited, an investment holding company, engages in the research and development, production, and sale of traditional Chinese medicine (TCM) and pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It operates through four segments: Yi Fang, Tian Jiang, Tong Ji Tang, and Medi-World. The company manufactures, manages, and sells concentrated TCM granules, and TCM health care products and decoction pieces, as well as TCM finished drugs. It also provides Chinese medical related healthcare solutions, including Chinese medical consultation and diagnosis, TCM physiotherapy, and prescription with concentrated TCM granules, TCM decoction pieces, and TCM healthcare product through its offline medical institutions. In addition, the company is involved in the retail sale of pharmaceuticals and decoction pharmaceutical; trading of pharmaceutical product; investment of the TCM health industry; sale of medical herb; provision of marketing, advertising and consulting of TCM; and property leasing activities. It sells its products under the Yi Fang, Tian Jiang, Tong Ji Tang, Medi-world, De Zhong, and Feng Liao Xing brands through hospitals and retail pharmacies. The company was formerly known as China Traditional Chinese Medicine Co. Limited and changed its name to China Traditional Chinese Medicine Holdings Co. Limited in 2016. China Traditional Chinese Medicine Holdings Co. Limited was founded in 1955 and is based in Wan Chai, Hong Kong.
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Earnings growth ≥10% supports improving profitability trajectory.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Net cash balance sheet provides flexibility for downturns and investment.
- Market Cap Total equity value of the company (share price × shares outstanding).
- HKD 11.48B
- Enterprise Value Operating value: market cap + total debt − cash.
- HKD 12.95B
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- HKD 16.51B
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- HKD 7.86B
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- HKD 1.82B
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- HKD 3.28
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- 0.01
- Dividend Yield Annual dividend ÷ share price. Reconciled using dividend per share when available.
- 15.00%
- Shares Outstanding
- 5.04B
- Float Shares
- 2.75B
- Implied Shares Outstanding
- 5.06B
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
4.69%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
11.00%
- Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
47.59%
- Profit Margin (TTM) Net income ÷ revenue over the last twelve months (reconciled when possible).
-
0.33%
- ROA Return on assets: net income ÷ total assets.
-
1.30%
- ROE Return on equity: net income ÷ shareholder equity.
-
0.09%
- Revenue Growth Year-over-year revenue growth.
-
-7.90%
- Earnings Growth (YoY) Strong Year-over-year earnings growth.
-
30.00%
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 1.75
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.17
- Total Cash Cash and equivalents.
- HKD 5.27B
- Total Debt Short + long-term interest-bearing debt.
- HKD 4.02B
- Net Debt Net Cash Total debt − cash (negative = net cash).
- HKD -1.26B
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- 2.21
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- HKD 2.58B
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- HKD 2.84B
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
15.65%
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
17.18%
- Cash Conversion (OpCF/EBITDA)
- 1.42
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.